Picture of OptimizeRx logo

OPRX — OptimizeRx News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyAdventurousSmall CapSuper Stock

Optimizerx Corp Expected To Post A Loss Of 13 Cents A Share: Earnings Preview

* OPTIMIZERx Corp  OPRX.OQ   OPRX.O  is expected to show a
rise in
quarterly revenue when it reports  results on May 14 for the
period ending March 31 2024
    * The Waltham Massachusetts-based  company is expected to
report a
39.4% increase in revenue to $18.132 million from $13 million a
year ago, according to the mean estimate from 5 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for OPTIMIZERx Corp is for a
loss
of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 23.1%
in the last three months. ​
    * Wall Street's median 12-month price target for OPTIMIZERx
Corp
is $16.00​, above​ its last closing price of $10.91. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.33        0.32       0.26      Missed  -19.5
 Sep. 30 2023  0.03        0.03       0.09      Beat    260
 Jun. 30 2023  -0.02       -0.02      -0.01     Beat    53.3​
 Mar. 31 2023  -0.08       -0.08      -0.09     Missed  -12.5
 ​​Dec.        0.25        0.24       0.25      Beat    3.6
 31 2022                                                
 Sep. 30 2022  0.03        0.04       0.07      Beat    90.7​
 Jun. 30 2022  0.09        0.09       0.04      Missed  -55.3
 Mar. 31 2022  -0.03       -0.01      -0.01     Met     15.3
 This summary was machine generated May 10 at 21:50 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on OptimizeRx

See all news